Answers are grounded in this paper and cite their sources.
Self-vaginal sampling (SVS) is a promising tool for cervical cancer prevention, offering a convenient and cost-effective alternative to traditional screening. With an 80% lifetime risk of HPV infection among women, SVS improves accessibility, particularly for marginalized communities and older women who are often excluded from routine screening. It reduces discomfort, empowers self-care, and provides insights into the vaginal microbiome, aiding in the detection of pathogens beyond HPV. However, challenges such as loss to follow-up, sampling errors, and misconceptions persist. Despite these hurdles, SVS remains a vital strategy for increasing screening participation and reducing cervical cancer disparities.
No takes yet. Share an insight, caveat, or question.
Patil‐Takbhate et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: